FGFR3 Mutation

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma1
FGFR3 Mutation	Infigratinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1910 Phase 1 study evaluated 132 patients who had advanced cancer with FGFR-aberrations treated with FGFR-inhibitor BGJ398. In the subgroup of eight patients with FGFR3-mutated bladder/urothelial cancer tr… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC	civic
Bladder Urothelial Carcinoma1
FGFR3 Mutation	Erdafitinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID10397 Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor JNJ-42756493. All 16 patients with … (full text at CIViC) PMID ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Bladder Carcinoma1

FGFR3 Mutation

Infigratinib

Predictive

Supports Sensitivity Response

accepted

EID1910

Phase 1 study evaluated 132 patients who had advanced cancer with FGFR-aberrations treated with FGFR-inhibitor BGJ398. In the subgroup of eight patients with FGFR3-mutated bladder/urothelial cancer tr… (full text at CIViC)

PMID 27870574 · Nogova et al., 2017 · Open in CIViC

civic

Bladder Urothelial Carcinoma1

FGFR3 Mutation

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID10397

Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor JNJ-42756493. All 16 patients with … (full text at CIViC)

PMID ·

Malignant Bladder Neoplasm2
FGFR3 Mutation	(prognostic)	Prognostic	B	Does Not Support Better Outcome	3	submitted	EID9258 The authors screened 85 superficial bladder tumor patients (35 with early-stage (stage Ta/grade 1-2) and 50 with an advanced stage (stage T1 or grade 3)) for variants in FGFR3 and TP53 genes. FGFR3 ac… (full text at CIViC) PMID 16278391 · Zieger et al., 2005 · Open in CIViC	civic
FGFR3 Mutation	Cisplatin + GemcitabineCombination	Predictive	B	Supports Sensitivity Response	3	accepted	EID7566 In this study, 52 patients with Muscle Invasive Bladder Cancer (MIBC) were randomly selected and administered neoadjuvant cisplatin and gemcitabine chemotherapy. 39 out of 52 patients showed pathologi… (full text at CIViC) PMID 29941343 · Yang et al., 2018 · Open in CIViC	civic

Malignant Bladder Neoplasm2

FGFR3 Mutation

(prognostic)

Prognostic

Does Not Support Better Outcome

submitted

EID9258

The authors screened 85 superficial bladder tumor patients (35 with early-stage (stage Ta/grade 1-2) and 50 with an advanced stage (stage T1 or grade 3)) for variants in FGFR3 and TP53 genes. FGFR3 ac… (full text at CIViC)

PMID 16278391 · Zieger et al., 2005 · Open in CIViC

civic

FGFR3 Mutation

Cisplatin + GemcitabineCombination

Predictive

Supports Sensitivity Response

accepted

EID7566

In this study, 52 patients with Muscle Invasive Bladder Cancer (MIBC) were randomly selected and administered neoadjuvant cisplatin and gemcitabine chemotherapy. 39 out of 52 patients showed pathologi… (full text at CIViC)

PMID 29941343 · Yang et al., 2018 · Open in CIViC

civic

Malignant Neoplasm1
FGFR1 Amplification OR FGFR2 Mutation OR v::FGFR1 Fusion OR FGFR2 Amplification OR FGFR3 Mutation OR FGFR3::v Fusion	Fexagratinib	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11675 In this NCI-MATCH trial subprotocol W, 48 patients harbouring FGFR1 or FGFR2 amplification (n = 20), FGFR2 or FGFR3 single-nucleotide variants (n=19), or FGFR1 or FGFR3 fusions (n=9) were treated with… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic

Malignant Neoplasm1

FGFR1 Amplification OR FGFR2 Mutation OR v::FGFR1 Fusion OR FGFR2 Amplification OR FGFR3 Mutation OR FGFR3::v Fusion

Fexagratinib

Predictive

Does Not Support Sensitivity Response

submitted

EID11675

In this NCI-MATCH trial subprotocol W, 48 patients harbouring FGFR1 or FGFR2 amplification (n = 20), FGFR2 or FGFR3 single-nucleotide variants (n=19), or FGFR1 or FGFR3 fusions (n=9) were treated with… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

civic

Transitional Cell Carcinoma2
FGFR3 Mutation	Erdafitinib	Predictive	A	Supports Sensitivity Response	4	rejected	EID7263 Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC) Open in CIViC	civic
FGFR3 Mutation	Erdafitinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID7422 In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC	civic

Transitional Cell Carcinoma2

FGFR3 Mutation

Erdafitinib

Predictive

Supports Sensitivity Response

rejected

EID7263

Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC)

Open in CIViC

civic

FGFR3 Mutation

Erdafitinib

Predictive

Supports Sensitivity Response

accepted

EID7422

In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a … (full text at CIViC)

PMID 31340094 · Loriot et al., 2019 · Open in CIViC

civic

Evidence by cancer (7 items)

Clinical significance (0)